Oncology

Novartis touts breast cancer win with “landmark” Kisqali results

Kicking off this year's American Society of Clinical Oncology's (ASCO) conference, Novartis has released data supporting the use of its…

FDA accepts Bristol Myers Squibb’s repotrectinib NDA for review

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s new drug application (NDA) for repotrectinib for priority…

University of Sydney will use AI to boost cancer drug research

The University of Sydney and Australian company Pharos Therapeutics have reached an agreement to leverage artificial intelligence (AI) to progress…

FivepHusion collaborates with Treehill, Syneos for Deflexifol

FivepHusion has collaborated with Treehill Partners and Syneos Health to strategically progress development and commercialisation of its chemotherapeutic formulation Deflexifol…

Daiichi Sankyo receives Japan’s MHLW approval for VANFLYTA

Daiichi Sankyo has received approval from Japan’s ministry of health, labour and welfare (MHLW) for VANFLYTA (quizartinib) to treat acute…

FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA

The US Food and Drug Administration (FDA) has granted priority review for Takeda and HUTCHMED’s new drug application (NDA) for…

Pyxis Oncology signs agreement to buy Apexigen

Pyxis Oncology has made a definitive agreement to buy biopharmaceutical company Apexigen, in a deal valued at nearly $16m. Pyxis…

China accepts Junshi’s sNDA for TNBC combination therapy

China’s National Medical Products Administration (NMPA) has accepted Shanghai Junshi Biosciences’ supplemental new drug application (sNDA) for toripalimab in combination…

FDA approves AbbVie-Genmab’s Epkinly to treat DLBCL

The US Food and Drug Administration (FDA) has granted approval to AbbVie and Genmab's Epkinly (epcoritamab-bysp) to treat relapsed or…

Forbion European Acquisition and enGene sign merger deal

Forbion European Acquisition has entered a definitive business combination agreement with biotechnology company enGene to create a combined biotechnology company…